An interventional study of PGx-guided post-operative pain management in Colorectal Cancer, Diverticular Disease and Crohn Disease, sponsored by The Cleveland Clinic. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-18.
Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Supportive care
Among 2,338 studies in Colorectal Neoplasms with a site in United States — 422 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,338 studies in Colorectal Neoplasms with a site in United States, this one is the 1,719th largest by enrollment of the 1,931 interventional ones, is one of 96 that started in 2018, is one of 533 with no phase, and was the 1,241st registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
This study's enrollment of 10 is below the median of 76 across 4,800 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →422 of the 2,338 studies in Colorectal Neoplasms with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →2,338 studies; the count open now beside each. This study's row is marked.
First in 1981; this study’s year is marked. 96 started in 2018.
Median enrollment 64 across the 1,931 interventional studies, 221 across the 324 observational. Of the 1,562 that completed or were terminated, 548 (35%) have results posted.
885 of 2,338 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 831 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
229 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Among the 2,338 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
The primary objectives of this study are to evaluate the potential for preoperative pharmacogenomics (PGx) testing to positively influence postoperative opioid use through visual analog scale (VAS) guided administration of narcotic equivalent and lower pain scores as measured by OBAS in patients undergoing major abdominal surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The control arm will receive no intervention and will follow standard of care for post-operative pain management.
The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
Genetic: PGx-guided post-operative pain management
Post-operative pain management as indicated by pharmacogenomic testing results.
Post-operative opioid use
Post-operative opioid use through visual analog scale guided administration of narcotic equivalent
Time frame: Post-op day 1
Overall Benefit of Analgesia Score (OBAS)
Time frame: Post-op day 1
Length of stay
Time frame: 30 days
Readmission rate
Time frame: 30 days
Functional status
Assessed through Duke Activity Status Index (DASI)
Time frame: 4 weeks and 3 months
Ran from Apr 2018 to primary completion in Jan 2019, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.